Ox-LDL increases OX40L in endothelial cells through a LOX-1-dependent mechanism

Abstract

Oxidative low-density lipoprotein (Ox-LDL) is a key risk factor for the development of atherosclerosis, and it can stimulate the expression of a variety of inflammatory signals. As a new and highly sensitive inflammation index, OX40L may be a key to understanding the mechanisms that regulate interactions between cells within the vessel wall and inflammatory mediators during the development of atherosclerosis. To investigate whether Ox-LDL regulates OX40L expression through an oxidized LDL-1 receptor (LOX-1)-mediated mechanism, we investigated the effect of different concentrations of Ox-LDL (50, 100, 150 µg/mL) on endothelial cell proliferation and apoptosis. Stimulation with Ox-LDL increased OX40L protein 1.44-fold and mRNA 4.0-fold in endothelial cells, and these effects were inhibited by blocking LOX-1. These results indicate that LOX-1 plays an important role in the chronic inflammatory process in blood vessel walls. Inhibiting LOX-1 may reduce blood vessel inflammation and provide a therapeutic option to limit atherosclerosis progression.

Atherosclerosis; Ox-LDL; LOX-1; OX40/OX40L; Polyinosinic acid

Introduction

The pathogenesis of atherosclerosis and preventive countermeasures are important therapeutic considerations. The inflammatory response plays a very important role in coronary atherosclerotic heart disease (¹). Atherosclerosis is a chronic disease characterized by an inflammatory hyperplasic response elicited by injury to vascular endothelial and smooth muscle cells in the artery wall, promoting local accumulation of oxidative low-density lipoprotein (Ox-LDL) (²-⁴). Accumulated Ox-LDL can stimulate the expression of a variety of inflammatory signals through activation of the lectin-like oxidized low-density lipoprotein-1 receptor (LOX-1) (⁵).

A new and highly sensitive inflammation index, OX40L, is present in almost all of the cells involved in atherosclerosis, including endothelial cells, lymphocytes, macrophages, and smooth muscle cells (⁶). Clinical studies have shown that levels of soluble OX40L in blood plasma are significantly higher in patients with acute coronary syndrome or stable angina than in the normal population. This suggests that OX40L serves as a key protein regulating the interaction between different cells in vascular tissue and inflammatory mediators in the development of atherosclerosis. In addition, OX40L has a very high sensitivity as a marker, indicating that it may be a valuable risk assessment factor for the development and progression of atherosclerosis (⁷).

During the progression of atherosclerosis, endothelial injury and Ox-LDL accumulation in the intima are critical initiating events. Moreover, Ox-LDL plays a role in regulation of the biological function of cells by stimulating cell membrane receptor-mediated endocytosis. Ox-LDL receptors include scavenger receptors A1 and A2, LOX-1, CD36, and CD68 (⁸). LOX-1, which was first described by Sawamura et al. (⁹) in 1997, mediates diverse biological effects induced by Ox-LDL stimulation of endothelial cells (¹⁰), including phagocytosis of apoptotic and aging endothelial cells and activation of diverse signaling pathways of inflammation (¹¹,¹²). For example, LOX-1 stimulates the upregulation of CD40 and CD40L, which are associated with inflammation in endothelial cells (¹³). Polyinosinic acid (Poly I) is a LOX-1 receptor antagonist, but only in combination with Ox-LDL (¹⁴). Poly I also inhibits vascular inflammation stimulated by Ox-LDL and thus delays the formation and development of atherosclerosis.

Because the influence and function of Ox-LDL in the OX40/OX40L signaling pathway is unclear, the purpose of this study was to clarify whether Ox-LDL is involved in the OX40/OX40L signaling pathways using an in vitro model of endothelial cell injury. In addition, we investigated the underlying mechanisms involved in order to provide a new theoretical basis and targets for drug therapy for prevention and treatment of atherosclerosis.

Material and Methods

Cell lines and reagents

Human umbilical vein endothelial cells (HUVECs) were obtained from Chongqing Medical University (Chongqing, China) and cultured in RPMI-1640 (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco). For Ox-LDL injury, HUVECs were treated with various concentrations of Ox-LDL (XieSheng Bio, China) and Poly I (Santa Cruz, USA) for 24 h. Cells were cultivated in a humidified atmosphere with 5% CO₂ at 37°C.

Cell proliferation assays

The cell counting kit (CCK-8, Beyotime Institute of Biotechnology, China) assay was used to determine cell proliferation. Increasing concentrations of Ox-LDL (50, 100, and 150 µg/mL) were added to cell cultures, which were then incubated for 24 h. Absorbance was detected with a microplate reader at a wavelength of 450 nm using a 96-well multichannel auto reader (Biotech Instruments, USA). The percentage inhibition of cell proliferation was determined by comparing the absorbance of treated with untreated controls as follows: Inhibition (%) = [1-(A of the experimental sample/A of the control)]×100%].

Assessment of cell cycle and apoptosis

Proliferating HUVECs were serum-starved overnight and treated with Ox-LDL (100 µg/mL) in complete media for 24 h. Following treatment, the cells were harvested and fixed in 70% ice-cold ethanol. The percentages of cells in the G₀/G₁-, S-, G₂- and M-phases were quantitated by flow cytometry.

The extent of apoptosis was evaluated by Annexin-V staining. HUVECs were incubated in the presence of Ox-LDL (100 µg/mL) for 24 h and stained with Annexin-V-fluorescein isothyocyanate (FITC) and propidium iodide (PI). Samples were analyzed by flow cytometry. The data shown are representative of at least three independent experimental sets.

Immunoblotting

HUVECs were plated in a culture flask 1 day before the experiment. The cells were then incubated for 24 h under the following conditions: a) no Ox-LDL, b) 100 µg/mL Ox-LDL, or c) 250 μg/μL Poly I plus 100 µg/mL Ox-LDL (¹⁴). The cells were washed three times with ice-cold PBS, lysed with RIPA lysis buffer (Beyotime) and placed on ice for 30 min. Proteins were separated by SDS-PAGE (12% gels) and subsequently transferred to a PVDF membrane (Millipore, USA). The membrane was blocked with 5% BSA in Tris-buffered saline and Tween-20 (10 mM Tris, pH 7.5, 140 mM NaCl, 0.05% Tween-20) for 2 h at room temperature. A rabbit polyclonal antibody against OX40L (1:1000, Santa Cruz) and a rabbit polyclonal antibody against LOX-1 (1:1000, Abcam, Hong Kong) were used as the primary antibodies, and horseradish peroxidase-conjugated goat anti-rabbit IgG was used as a secondary antibody. BeyoECL Plus (Beyotime) was used for antibody detection according to the manufacturer's instructions.

Immunocytochemistry

Following the same stimulation conditions described above, HUVECs were fixed in 4% paraformaldehyde for 20 min, and washed three times in PBS. A rabbit polyclonal primary antibody against OX40L (1:1000, Santa Cruz) was added at 4°C overnight. Cells were washed three times in PBS and incubated with the blocking solution, which included FITC-conjugated goat anti-rabbit IgG (CWBio, China), at 37°C for 2 h. Cells were washed three times in PBS and incubated with PI at 37°C for 5 min. Cells were observed with a laser confocal microscope, and the average fluorescence value of eight cells from a random selection was calculated. All images were acquired under identical conditions from a microscope image system.

RNA isolation and real-time qPCR

Total RNA was isolated from cultured HUVECs using RNAiso Plus (Takara, Japan) according to the manufacturer's instructions. First-strand complementary DNA (cDNA) was synthesized using oligo-dT primers and M-MLV reverse transcriptase (Takara). Quantitative PCR was performed with SYBR green PCR Master Mix (Takara). The following primers were used to amplify OX40L cDNA: sense: 5′-CGGGCAGGTCTACTTTGGAG-3′ and antisense:5′-CAGGTCACTGTCCCAGCATC-3′; β-actin cDNA: sense: 5′-CCACGAAACTACCTTCAACTCC-3′ and antisense:5′-GTGATCTCCTTCTGCATCCTGT-3′. PCR was performed using the following PCR conditions: denaturing at 95°C for 30 s, annealing at 60°C for 20 s, and elongation at 70°C for 10 s. The mRNA levels of OX40L were normalized to β-actin.

Statistical analysis

Data were reported as means±SD using SPSS 17.0. Comparative data were analyzed by multivariate analysis, and the Student t-test was used for paired data. A value of P<0.05 was considered to be statistically significant.

Results

Ox-LDL inhibited proliferation of HUVECs

Ox-LDL, which plays a key role in the endothelial injury response, inhibited HUVEC proliferation. There was a decrease in cell number and an increase in cell apoptosis when cells were stimulated by Ox-LDL. In contrast, normal HUVECs adhered, adopted a spindle or pentagonal shape, and proliferated at normal rates (Figure 1A and B). Cell proliferation also decreased with increased concentrations of Ox-LDL (Table 1).

Figure 1
HUVEC shape by inverted microscopy. A, Control HUVECs showing normal adherent growth with a spindle or pentagonal shape. B, HUVECs incubated with Ox-LDL (150 µg/mL) for 24 h. The cells are shrunken, with an increased rate of cell apoptosis indicated by an increased formation of apoptotic bodies. HUVECs: human umbilical vein endothelial cells; Ox-LDL: oxidative low-density lipoprotein.

Ox-LDL influenced the cell cycle and apoptosis rate of HUVECs

To further evaluate the effect of endothelial injury, the cell cycle and apoptosis rate were determined by Annexin-V staining. As shown in Figure 2A and B, the S phase population of HUVECs incubated with Ox-LDL (100 µg/mL) for 24 h was significantly greater than in the control group (Table 2), suggesting that cells were blocked in the S phase. In addition, flow cytometry revealed that the apoptosis rate of HUVECs incubated with Ox-LDL was higher than in HUVECs incubated under normal conditions (Figure 3 and Table 2).

Figure 2
A, Cell cycle of normal HUVECs. B, HUVECs incubated with Ox-LDL (100 µg/mL) for 24 h. HUVECs: human umbilical vein endothelial cells; Ox-LDL: oxidative low-density lipoprotein.

Figure 3
A, Apoptosis rates of normal HUVECs.B, HUVECs incubated with Ox-LDL (100 µg/mL) for 24 h. Rates increased from 5.26% in control to 15.69% in the Ox-LDL-treated cells. HUVECs: human umbilical vein endothelial cells; Ox-LDL: oxidative low-density lipoprotein; PI: propidium iodide.

Ox-LDL upregulated OX40L expression via LOX-1

To quantify the expression of OX40L during atherosclerotic injury in endothelial cells, we constructed a cell injury model by stimulating HUVECS with 100 µg/mL Ox-LDL for 24 h. OX40L protein and mRNA expression in HUVECs were increased compared with expression in the normal control group (Figures 4A, 5A and B, and 6A). Furthermore, OX40L was expressed on HUVEC cell membranes (Figure 5).

Figure 4
A, OX40L expression levels in HUVECs treated with 1) no Ox-LDL (untreated control); 2) 100 µg/mL Ox-LDL, and 3) 250 μg/μL Poly I plus 100 µg/mL Ox-LDL. B, The expression of OX40L in group 2 was increased compared with group 1, while OX40L protein expression in group 3 was decreased compared with group 2 (n=4; *P<0.05, t-test). HUVECs: human umbilical vein endothelial cells; Ox-LDL: oxidative low-density lipoprotein; Poly I: polyinosinic acid.

Figure 5
Change in OX40L expression with A, no Ox-LDL;B, 100 µg/mL Ox-LDL; C, 250 μg/μL Poly I plus 100 µg/mL Ox-LDL. The cells were observed by laser confocal microscope (bar=75 μm). Green fluorescence indicates OX40L protein. Red fluorescence indicates nucleolus. Red and green fluorescence show the location and volume of OX40L protein. D, Average fluorescence value of 8 randomly selected cells. OX40L was expressed on HUVEC membranes. OX40L protein expression in group B was increased compared to group A, while the expression of OX40L in group C was decreased compared to group B (n=4; *P<0.05, t-test). HUVECs: human umbilical vein endothelial cells; Ox-LDL: oxidative low-density lipoprotein; Poly I: polyinosinic acid.

Figure 6
A, Quantification cycles of OX40L mRNA.B, OX40L expression with no Ox-LDL (Control), 100 µg/mL Ox-LDL, and 250 μg/μL Poly I plus 100 µg/mL Ox-LDL. OX40L mRNA expression in Ox-LDL was increased compared to control while OX40L mRNA expression in Ox-LDL+Poly 1 was decreased compared to Ox-LDL (n=4; *P<0.05, t-test). Ox-LDL: oxidative low-density lipoprotein; Poly I: polyinosinic acid.

To explore the role of LOX-1 in the upregulation of OX40L during atherosclerotic endothelial cell injury, we pretreated HUVECs with 250 μg/μL Poly I at 1 h to partially block the LOX-1 receptor (¹⁵). Then, 100 µg/mL Ox-LDL was added to the HUVECs for 24 h. Following these treatments, OX40L mRNA and protein decreased compared with the untreated group (Figures 4A, 5B and C, and 6A). The results of the OX40L assay are shown in Figures 4B, 5D, and 6B.

To confirm that Poly I produced its effects by blocking the LOX-1 receptor, we incubated HUVECs for 24 h under the following conditions: 1) no Ox-LDL, 2) 100 µg/mL Ox-LDL, and 3) 250 μg/μL Poly I plus 100 µg/mL Ox-LDL. The results showed that LOX-1 protein expression in group 2 increased compared to group 1, and LOX-1 protein in group 3 decreased compared with group 2 (Figure 7).

Figure 7
A, LOX-1 expression levels in HUVECs treated with 1) no Ox-LDL (untreated control); 2) 100 µg/mL Ox-LDL, and 3) 250 μg/μL Poly I plus 100 µg/mL Ox-LDL. B, The expression of LOX-1 in group 2 was increased compared to group 1. LOX-1 protein expression in group 3 was decreased compared to group 2 (n=4; *P<0.05, t-test). LOX-1: oxidized low-density lipoprotein-1 receptor; HUVECs: human umbilical vein endothelial cells; Ox-LDL: oxidative low-density lipoprotein; Poly I: polyinosinic acid.

Discussion

The goal of this study was to determine whether Ox-LDL stimulated the expression of OX40L in HUVECs via a LOX-1-dependent mechanism. The major findings of this study were: 1) Ox-LDL significantly suppressed HUVEC proliferation, and the cells were arrested in the S phase of the cell cycle; 2) stimulation with Ox-LDL increased OX40L protein and mRNA expressions in endothelial cells; and 3) this increase was inhibited partially by blocking LOX-1 with Poly I. Together, these results suggest that Ox-LDL regulates OX40L expression through a LOX-1-mediated mechanism. Furthermore, the inhibition of HUVEC proliferation and stimulation of apoptosis by Ox-LDL, which is closely related to the progression of atherosclerosis, may be affected by the expression of OX40L.

OX40, which is a type I transmembrane glycoprotein, and OX40L, which is a type II transmembrane glycoprotein, are costimulatory molecules. OX40L is mainly expressed in mature, antigen-presenting cells, activated B cells, vascular endothelial cells, umbilical vein endothelial cells (HUVEC), and macrophages (¹⁶).

LOX-1 shares no structural homology with any other lipoprotein receptor. In addition, LOX-1 can only bind to Ox-LDL and cannot bind to natural LDL or acetylated LDL. Furthermore, LOX-1 can mediate Ox-LDL-related effects, such as vascular endothelial cell dysfunction, foam cell formation, apoptosis, and inflammatory mediator secretion. As such, LOX-1 plays a key role in atherosclerotic plaque formation and development (¹⁷,¹⁸).

In this study, when HUVECs were cultured with Ox-LDL, OX40L protein and mRNA expression increased markedly compared with the control group. In contrast, OX40L mRNA and protein expression decreased when HUVECs were pretreated with Poly I, a partial LOX-1 receptor inhibitor. These results show that Ox-LDL upregulates OX40L in HUVECs and that this effect is mediated by LOX-1. Blocking the LOX-1 receptor may therefore be a viable method to reduce the inflammatory response in atherosclerosis.

This study showed, for the first time, the relationship between Ox-LDL and OX40L expression in HUVECs. Moreover, we found that LOX-1 mediated a specific cell signal transduction pathway. These results highlight the important role of LOX-1 in the regulation of OX40L expression during endothelial injury, indicating that LOX-1 may also play a role in the development of atherosclerosis by altering endothelial cell function.

Ox-LDL has additional targets and functions. When Ox-LDL combines with LOX-1, the nuclear transcription factor NF-κB is activated (¹⁹). NF-κB is a relevant transcription factor for a variety of inflammatory mediators. Our findings indicate that an increase in OX40L expression mediated by LOX-1 may be an intermediate link in the inflammatory response that occurs during the development of atherosclerotic plaque. Future studies are needed to examine the effects of NF-κB activation, which occurs downstream of LOX-1. Nonetheless, reducing the secretion of inflammatory factors by blocking or limiting LOX-1 expression on the surfaces of endothelial cells in atherosclerotic plaques may be a novel drug treatment target for atherosclerosis and may provide new clinical treatment strategies for acute coronary syndrome.

We wish to thank Professor Kang-Hua Ma, Dr. Su-Xin Luo, and Professor Wei-Xue Tang for their helpful discussions and technical assistance in this study. Research supported by the Department of Cardiology, First Affiliated Hospital, Chongqing Medical University, China.

References

• ¹
  Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res 2008; 103: 1220-1231, doi: 10.1161/CIRCRESAHA.108.182428.
  » https://doi.org/10.1161/CIRCRESAHA.108.182428
• ²
  Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126, doi: 10.1056/NEJM199901143400207.
  » https://doi.org/10.1056/NEJM199901143400207
• ³
  Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993-997, doi: 10.1136/heart.89.9.993.
  » https://doi.org/10.1136/heart.89.9.993
• ⁴
  Liuzzo G. Atherosclerosis: an inflammatory disease. Rays 2001; 26: 221-230.
• ⁵
  Hayashida K, Kume N, Minami M, Kita T. Lectin-like oxidized LDL receptor-1 (LOX-1) supports adhesion of mononuclear leukocytes and a monocyte-like cell line THP-1 cells under static and flow conditions. FEBS Lett 2002; 511: 133-138, doi: 10.1016/S0014-5793(01)03297-5.
  » https://doi.org/10.1016/S0014-5793(01)03297-5
• ⁶
  Wang X, Ria M, Kelmenson PM, Eriksson P, Higgins DC, Samnegard A, et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005; 37: 365-372, doi: 10.1038/ng1524.
  » https://doi.org/10.1038/ng1524
• ⁷
  Shi JZ, Wang LY, Zhu Y, Zhao CY, Liu W, Jiang SL, et al. OX40 ligand levels and high-sensitivity C-reactive protein levels in blood from local coronary plaque and the femoral artery in patients with acute coronary syndrome or stable angina. J Int Med Res 2011; 39: 1275-1283, doi: 10.1177/147323001103900415.
  » https://doi.org/10.1177/147323001103900415
• ⁸
  Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785-791.
• ⁹
  Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997; 386: 73-77, doi: 10.1038/386073a0.
  » https://doi.org/10.1038/386073a0
• ¹⁰
  Murphy JE, Vohra RS, Dunn S, Holloway ZG, Monaco AP, Homer-Vanniasinkam S, et al. Oxidised LDL internalisation by the LOX-1 scavenger receptor is dependent on a novel cytoplasmic motif and is regulated by dynamin-2. J Cell Sci 2008; 121: 2136-2147, doi: 10.1242/jcs.020917.
  » https://doi.org/10.1242/jcs.020917
• ¹¹
  Reiss AB, Anwar K, Wirkowski P. Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) in atherogenesis: a brief review. Curr Med Chem 2009; 16: 2641-2652, doi: 10.2174/092986709788681994.
  » https://doi.org/10.2174/092986709788681994
• ¹²
  Xu X, Gao X, Potter BJ, Cao JM, Zhang C. Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler Thromb Vasc Biol 2007; 27: 871-877, doi: 10.1161/01.ATV.0000259358.31234.37.
  » https://doi.org/10.1161/01.ATV.0000259358.31234.37
• ¹³
  Mendez-Cruz AR, Paez A, Jimenez-Flores R, Reyes-Reali J, Varela E, Cerbulo-Vazquez A, et al. Increased expression of inflammation-related co-stimulatory molecules by HUVECs from newborns with a strong family history of myocardial infarction stimulated with TNF-alpha and oxLDL. Immunol Lett 2007; 111: 116-123, doi: 10.1016/j.imlet.2007.06.008.
  » https://doi.org/10.1016/j.imlet.2007.06.008
• ¹⁴
  Moriwaki H, Kume N, Sawamura T, Aoyama T, Hoshikawa H, Ochi H, et al. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler Thromb Vasc Biol 1998; 18: 1541-1547, doi: 10.1161/01.ATV.18.10.1541.
  » https://doi.org/10.1161/01.ATV.18.10.1541
• ¹⁵
  Wang M, Lu YJ. Effects of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) on MMP-9 expression in cultured THP-1 monocyte-derived macrophages and the protective effect of simvastatin. J Shandong University (Health Sciences) 2008; 12: 1136-1140.
• ¹⁶
  Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3: 609-620, doi: 10.1038/nri1148.
  » https://doi.org/10.1038/nri1148
• ¹⁷
  Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 2006; 69: 36-45, doi: 10.1016/j.cardiores.2005.09.006.
  » https://doi.org/10.1016/j.cardiores.2005.09.006
• ¹⁸
  Ishino S, Mukai T, Kume N, Asano D, Ogawa M, Kuge Y, et al. Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability - analysis in hypercholesterolemic rabbits. Atherosclerosis 2007; 195: 48-56, doi: 10.1016/j.atherosclerosis.2006.11.031.
  » https://doi.org/10.1016/j.atherosclerosis.2006.11.031
• ¹⁹
  Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 2000; 20: 1116-1122, doi: 10.1161/01.ATV.20.4.1116.
  » https://doi.org/10.1161/01.ATV.20.4.1116

• First published online September 16, 2013.

Publication Dates

• Publication in this collection
  19 Sept 2013
• Date of issue
  Sept 2013

History

• Received
  14 Nov 2012
• Accepted
  7 June 2013